Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
11C-YJH08 PET Imaging in Advanced Solid Tumors
NCT04927663Phase 1Terminated
- Sponsor
- Rahul Aggarwal
- Start
- Aug 2021
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of 11C-YJH08 in solid tumor and metastatic castration-resistant prostate cancer (mCRPC) (3 cohorts), sponsored by Rahul Aggarwal. Primary endpoints: Sensitivity of 11C-YJH08 PET in Metastatic Lesion Detection, Median Percent Change From Baseline in Standardized Uptake Value (SUV)Max up to 24 months and 1 more. Started Aug 2021; status: terminated.
02
Drugs
11C-YJH08
03
Conditions
solid tumormetastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04927663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04927663.